Shilpa Medicare Intrinsic Value
Shilpa Medicare intrinsic value. Shilpa Medicare (SHILPAMED) median intrinsic value is ₹1801.40 from 10 valuation models (range ₹270–₹2252), vs current price ₹900.70 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse Shilpa Medicare financial data for revenue, profit, balance sheet and cash flow data.
SHILPAMED Valuation Methods Summary — DCF, Graham Number & P/E
Shilpa Medicare intrinsic value across 10 models vs current price ₹900.70 — upside/downside and value range per method. For current market price and key ratios, visit SHILPAMED share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹356.40 | ₹285.12 - ₹427.68 | -60.4% | EPS: ₹16.20, Sector P/E: 22x |
| Book Value Method | asset | ₹2251.75 | ₹2026.58 - ₹2476.93 | +150.0% | Book Value/Share: ₹1295.50, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1801.40 | ₹1621.26 - ₹1981.54 | +100.0% | Revenue/Share: ₹1076.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1801.40 | ₹1621.26 - ₹1981.54 | +100.0% | EBITDA: ₹604.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2251.75 | ₹1801.40 - ₹2702.10 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹270.21 | ₹243.19 - ₹297.23 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹270.21 | ₹243.19 - ₹297.23 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1801.40 | ₹1621.26 - ₹1981.54 | +100.0% | ROE: 12.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹687.18 | ₹618.46 - ₹755.90 | -23.7% | EPS: ₹16.20, BVPS: ₹1295.50 |
| Dividend Yield Method | dividend | ₹270.21 | ₹243.19 - ₹297.23 | -70.0% | DPS: ₹0.60, Target Yield: 2.5% |
SHILPAMED Intrinsic Value vs Market Price — All Valuation Models
Shilpa Medicare fair value range ₹270–₹2252 vs current market price ₹900.70 across 10 valuation models. Analyse SHILPAMED shareholder distribution to track promoter, FII and institutional holdings.
SHILPAMED Intrinsic Value Analysis — Undervalued or Overvalued?
Shilpa Medicare median intrinsic value ₹1801.40, current price ₹900.70 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of SHILPAMED?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Shilpa Medicare (SHILPAMED) is ₹1801.40 (median value). With the current market price of ₹900.70, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹270.21 to ₹2251.75, indicating ₹270.21 - ₹2251.75.
Is SHILPAMED undervalued or overvalued?
Based on our multi-method analysis, Shilpa Medicare (SHILPAMED) appears to be trading below calculated value by approximately 100.0%.
SHILPAMED Financial Health — Key Ratios vs Industry Benchmarks
Shilpa Medicare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 12.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.58x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SHILPAMED Cash Flow Quality — Operating & Free Cash Flow
Shilpa Medicare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹342 Cr | ₹173 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹132 Cr | ₹33 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹137 Cr | ₹52 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹180 Cr | ₹64 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹105 Cr | ₹-38 Cr | Positive Operating Cash Flow | 6/10 |